BSF Enterprise PLC Application for Trading on US OTCQB Venture Market (4383S)
March 09 2023 - 2:53AM
UK Regulatory
TIDMBSFA
RNS Number : 4383S
BSF Enterprise PLC
09 March 2023
9 March 2023
BSF Enterprise PLC
("BSF" or the "Company")
Application for Trading on US OTCQB Venture Market
BSF (LSE: BSFA), the Main Market listed biotech company and the
owner of pioneering UK-based clinical and cellular agriculture
company 3D Bio-Tissues, is pleased to announce that is has
submitted an application for trading the Company's Ordinary Shares
("Ordinary Shares") on the OTCQB Venture Market in the United
States.
Trading on the OTCQB market will allow BSF to access one of the
world's largest investment markets, expanding its reach into a
broader pool of investors and creating the potential for greater
liquidity in the Company's shares. Shares will also be available to
US investors during US trading hours, priced in US dollars, thereby
easing cross-border trading, and providing the potential to enhance
liquidity still further.
There is no capital raise associated with BSF trading on the
OTCQB market and BSF's Ordinary Shares will continue to trade on
its primary listing, the Main Market of the London Stock Exchange,
under the ticker BSFA.
Che Connon, Managing Director of BSF Enterprise and CEO at 3D
Bio Tissues, commented: "Joining the OTCQB market provides BSF with
access to a wider investor audience which in turn can improve our
liquidity. In addition, it helps raise our international profile,
which could prove invaluable given the global potential for our
market leading cellular agriculture products as we open up sales
channels across key global markets."
Further Information on BSF's application and the OTCQB market
below:
As a Foreign Private Issuer, BSF's onboarding to the OTC Markets
is based on satisfaction of the requirements for OTCQB as
applicable to international reporting companies including
satisfaction of the criteria for the exemption under the US
Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b)
exemption includes the disclosure obligation to ensure that certain
information made public or distributed under home market
regulations is made publicly available on the Company's website or
other electronic information delivery system in English. Thus, the
Company will have no additional reporting obligations and incur
minimal ongoing costs, compared to traditional major exchanges.
As a verified market, the OTCQB offers transparent trading for
companies that have met a minimum bid price test, are current in
their financial reporting and have undergone an annual verification
and management certification process. The cross-trading facility is
provided through OTC Markets Group Inc., located in New York. OTC
Markets operates the world's largest electronic interdealer
quotation system for US broker dealers and offers multiple media
channels to increase the visibility of OTC-listed companies. Online
brokers such as Ameritrade, Fidelity Investments, Tradestation,
Charles Schwab and E-trade all offer OTCQB trades. US investors can
find real-time quotes, market information and access current
company news and developments on a BSF page on the OTC Markets
website after the application is completed .
BSF has appointed B. Riley Financial Company as its OTCQB
Sponsor and is advised by Ince Lawyers in London.
Additional information about the OTCQB market can be found
at:
www.otcmarkets.com/learn/market-101
-Ends-
For further enquiries, please visit www.bsfenterprise.com or contact:
BSF Enterprise PLC Via SEC Newgate
below
Geoff Baker - Non-Executive Director
Che Connon - Executive Director
Shard Capital (Broker)
Damon Heath 0203 971 7000
SEC Newgate (Financial Communications)
Bob Huxford 020 3757 6882
Elisabeth Cowell BSF@secnewgate.co.uk
George Esmond
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next
generation of biotechnological solutions - using cell-based tissue
engineering to help generate cultured meat, lab-grown leather, as
well as human corneas, collagen growth and skin substitutes, as
part of a radical transformation to deliver sustainable solutions
across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help
restore vision to millions of people. Building on this success, it
aims to produce the UK's first high quality lab-grown meat from its
laboratory in Newcastle the next 12 months, transforming the
meat-production industry towards an ethical and sustainable
practice.
BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as
well as through M&A. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers,
wholesalers and distributors to help manufacture the products at
scale.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUACWUPWURB
(END) Dow Jones Newswires
March 09, 2023 03:53 ET (08:53 GMT)
Bsf Enterprise (LSE:BSFA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bsf Enterprise (LSE:BSFA)
Historical Stock Chart
From Dec 2023 to Dec 2024